Latest News

KALBE EDUCATION BRAIN FOG ALERT AS A LONG TERM EFFECT POST COVID-19

KALBE EDUCATION BRAIN FOG ALERT AS A LONG TERM EFFECT POST COVID-19


Press Release  No. 046/KFCP-DIR/PR/VIII/21


Jakarta, August 18, 2021, PT Kalbe Farma Tbk (Kalbe) held an online health education event with the media with the theme “Beware of Brain Fog As a Long-Term Effect of Post-COVID-19, which featured the speakers Dr. dr. Yuda Turana, Sp.S – Neurologist Atmajaya Hospital (Counselor – ALZI/Alzheimer Indonesia) and Nandhita Octavia Nugriani, S.T., B.Eng – Product Management PT Kalbe Farma Tbk. This education aims to provide information to the public about the symptoms of Brain Fog as a long-covid phenomenon after recovering from a COVID-19 infection, socializing how Brain Fog can occur, the possible dangers, and how to get treatment tips to prevent these symptoms from becoming one of the risks of early-onset dementia as well as introducing the health supplement Citicoline (Brainact Odis®) which functions to help Brain Fog therapy with safe side effects, fresh taste, and the benefit of it being quickly dissolved in the mouth without the need for drinking water (practical).

 

"Kalbe is committed to providing health education to increase knowledge and awareness to the public in maintaining health, from prevention to treatment," said Anita Lestari Halim, Senior Product Manager of PT Kalbe Farma, Tbk. "In the midst of the COVID-19 pandemic, many people were confirmed of COVID-19 but prior to recovery they have to undergo therapy to reduce the frequency of Brain Fog symptoms as a phenomenon of long covid, and always pay attention to health protocols in their activities. Therefore, we must continue to maintain our health and restore our immune system with a healthy lifestyle, regular exercise, and fulfilling our nutritional needs from food & supplements,” Anita continued.

 

"Not all patients who recover from Covid-19 infection are symptom-free after recovering. Many of them reported experiencing ongoing fatigue and dizziness. The decline in cognitive function becomes a long-term clinical impact, known as Brain Fog, which is a symptom related to brain function in the ability to concentrate, memory, and communication, "said Dr. dr. Yuda Turana, Sp.S – Neurologist at Atmajaya Hospital (Counselor – ALZI). "The causes of cognitive impairment are multifactorial, so adopting a healthy, physically, and psychologically healthy lifestyle is very necessary during the current COVID-19 pandemic," added Dr. dr. Yuda.

 

"One of the efforts to prevent the occurrence of early dementia due to symptoms of Brain Fog as a long covid phenomenon after recovering from COVID-19 infection is to maintain the body's immune system to remain productive by consuming health supplements," said Nandhita Octavia Nugriani, ST., B.Eng – Product Management PT Kalbe Farma Tbk. “Citicoline health supplement (Brainact Odis®) which functions to help Brain Fog therapy with safe side effects, fresh taste, and benefits of it dissolving quickly in the mouth without the need for drinking water (practical) is very suitable for consumption to maintain endurance and stay productive, especially in this pandemic era," concluded Nandhita. 

 

 

Kalbe at a glance

PT Kalbe Farma Tbk ("Kalbe") was established in 1966 and is one of the largest listed pharmaceutical companies in Southeast Asia. Kalbe has four main divisions that handle reliable and varied brand portfolio: prescription medicines (Cefspan, Brainact, Broadced, etc.); health product division that handles over-the-counter medication (Promag, Mixagrip, Komix, Woods, Fatigon, etc.); multivitamins (Fatigon, H2, XonCe, Hevit-C, JossC1000, etc.);  as well as supplement and ready-to-consume drinks (Hydro Coco, Extra Joss); nutrition division (ChilKid, Prenagen, Diabetasol, Zee, etc,); and distribution division. Kalbe now has more than 40 subsidiaries, 14 production facilities with international standards, and employs approximately 17,000 employees, spread in more than 76 branches throughout Indonesia. Since 1991, Kalbe is listed on the Indonesia Stock Exchange (IDX: KLBF).

Print
1603 Rate this article:
No rating

Please login or register to post comments.

Name:
Email:
Subject:
Message:
x